Lymphokine-activated killer cells in autologous bone marrow transplantation. Evidence against inhibition of engraftment in vivo.
Lymphokine activated killer cells have potent antitumor effect both in vitro and in vivo. They have been reported to suppress bone marrow (BM) progenitor cell activity (PCA) in vitro, thus raising concern about the feasibility of their use after autologous bone marrow transplantation. The present study was carried out to evaluate the effect of LAK cells on BM engraftment in a syngeneic BMT setting in mice. LAK cells supplemented with or without exogenous interleukin-2 therapy did not impair the hematopoietic reconstitution or survival of mice undergoing BMT. LAK cells also did not reduce the PCA of the engrafted BM. LAK cell therapy did not cause graft-versus-host disease. Finally, LAK cells supplemented with IL-2 therapy improved the graft-versus-leukemia effect. These findings suggest that LAK cells plus IL-2 therapy after BMT does not impede hematopoiesis and should be evaluated as an adjuvant therapy with the aim of eradication of minimal residual disease after autologous BMT.
Charak
B S
BS
Bone Marrow Transplantation Program, Georgetown University, Washington, D.C. 20007.
Brynes
R K
RK
Chogyoji
M
M
Mazumder
A
A
D000818:Animals; D016026:Bone Marrow Transplantation / Q000473:pathology*; D005260:Female; D006410:Hematopoiesis / Q000276:immunology; D007167:Immunotherapy; D016219:Immunotherapy, Adoptive; D015979:Killer Cells, Lymphokine-Activated / Q000166:cytology* / Q000502:physiology*; D007942:Leukemia, Experimental / Q000628:therapy; D008546:Melanoma, Experimental / Q000628:therapy; D051379:Mice; D008810:Mice, Inbred C57BL; D013154:Spleen / Q000166:cytology; D013234:Stem Cells / Q000166:cytology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014182:Transplantation, Autologous